Context Capital Stock from 2010 to 2025

CNTX Stock  USD 0.84  0  0.12%   
Context Therapeutics Capital Stock yearly trend continues to be fairly stable with very little volatility. Capital Stock will likely drop to about 10.7 K in 2025. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals
 
Capital Stock  
First Reported
2010-12-31
Previous Quarter
18.4 K
Current Value
10.7 K
Quarterly Volatility
7.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Context Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Context Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 435.1 K, Selling General Administrative of 9.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.44. Context financial statements analysis is a perfect complement when working with Context Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Context Therapeutics Correlation against competitors.
For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.

Latest Context Therapeutics' Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Context Therapeutics over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Context Therapeutics' Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Context Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capital Stock10 Years Trend
Slightly volatile
   Capital Stock   
       Timeline  

Context Capital Stock Regression Statistics

Arithmetic Mean5,032
Geometric Mean1,079
Coefficient Of Variation146.21
Mean Deviation6,473
Median324.00
Standard Deviation7,357
Sample Variance54.1M
Range18K
R-Value0.77
Mean Square Error23.4M
R-Squared0.60
Significance0.0004
Slope1,194
Total Sum of Squares812M

Context Capital Stock History

202510.7 K
202418.4 K
202116 K
2020 332.0

Other Fundumenentals of Context Therapeutics

Context Therapeutics Capital Stock component correlations

0.97-0.12-0.46-0.410.070.08-0.590.34-0.540.97-0.570.080.480.02-0.280.430.180.28
0.970.06-0.52-0.430.03-0.07-0.780.26-0.610.97-0.73-0.070.670.0-0.430.550.380.43
-0.120.060.320.05-0.78-0.53-0.45-0.880.350.12-0.08-0.530.56-0.72-0.880.750.910.88
-0.46-0.520.320.28-0.480.30.51-0.630.66-0.380.630.3-0.38-0.46-0.270.190.050.26
-0.41-0.430.050.28-0.350.090.37-0.30.27-0.370.310.09-0.32-0.390.15-0.38-0.09-0.16
0.070.03-0.78-0.48-0.350.330.040.92-0.62-0.16-0.310.33-0.140.990.63-0.48-0.61-0.63
0.08-0.07-0.530.30.090.330.380.35-0.11-0.10.21.0-0.270.240.3-0.25-0.41-0.33
-0.59-0.78-0.450.510.370.040.380.010.61-0.660.890.38-0.920.030.66-0.66-0.72-0.67
0.340.26-0.88-0.63-0.30.920.350.01-0.680.11-0.350.35-0.150.870.68-0.52-0.66-0.68
-0.54-0.610.350.660.27-0.62-0.110.61-0.68-0.410.9-0.11-0.41-0.59-0.050.040.050.05
0.970.970.12-0.38-0.37-0.16-0.1-0.660.11-0.41-0.55-0.10.57-0.19-0.470.590.380.47
-0.57-0.73-0.080.630.31-0.310.20.89-0.350.9-0.550.2-0.72-0.310.34-0.32-0.36-0.34
0.08-0.07-0.530.30.090.331.00.380.35-0.11-0.10.2-0.270.240.3-0.25-0.41-0.33
0.480.670.56-0.38-0.32-0.14-0.27-0.92-0.15-0.410.57-0.72-0.27-0.15-0.710.730.840.72
0.020.0-0.72-0.46-0.390.990.240.030.87-0.59-0.19-0.310.24-0.150.59-0.45-0.59-0.59
-0.28-0.43-0.88-0.270.150.630.30.660.68-0.05-0.470.340.3-0.710.59-0.94-0.91-1.0
0.430.550.750.19-0.38-0.48-0.25-0.66-0.520.040.59-0.32-0.250.73-0.45-0.940.840.94
0.180.380.910.05-0.09-0.61-0.41-0.72-0.660.050.38-0.36-0.410.84-0.59-0.910.840.92
0.280.430.880.26-0.16-0.63-0.33-0.67-0.680.050.47-0.34-0.330.72-0.59-1.00.940.92
Click cells to compare fundamentals

About Context Therapeutics Financial Statements

Context Therapeutics investors use historical fundamental indicators, such as Context Therapeutics' Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Context Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Stock18.4 K10.7 K
Issuance Of Capital Stock61.4 M31 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.